Alkeran, Melphalan Newswire

Alkeran, Melphalan Newswire

Comprehensive Real-Time News Feed for Alkeran, Melphalan (generic).

Results 1 - 20 of 120 in Alkeran, Melphalan (generic)

  1. Delcath Systems Inc. (DCTH) Trading 27.3% HigherRead the original story w/Photo

    16 hrs ago | Daily Political

    Delcath Systems Inc. traded up 27.3% during trading on Thursday . The stock traded as high as $4.49 and last traded at $3.87, with a volume of 259,251 shares.

    Comment?

  2. Comment on 'The incidence of leukaemia in women with BRCA1 and...Read the original story

    Tuesday Jul 26 | British Journal of Cancer

    Comment on ‘The incidence of leukaemia in women with BRCA1 and BRCA2 mutations: an International Prospective Cohort Study’ It is important to identify breast cancer patients at undue risk for leukaemia associated with breast cancer chemotherapy to measure risks vs benefits of chemotherapy. Iqbal et al conclude that although leukaemia in BRCA2 carriers is primarily caused by breast cancer chemotherapy, it is so rare that BRCA mutation carriers can be treated according to standard protocols.

    Comment?

  3. Delcath Systems Inc. (DCTH) Hits New 52-Week Low at $3.32Read the original story w/Photo

    Yesterday | Daily Political

    Delcath Systems Inc. shares reached a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $3.32 and last traded at $3.34, with a volume of 21,159 shares changing hands.

    Comment?

  4. Delcath Systems Inc. (DCTH) Trading Down 5.4%Read the original story w/Photo

    Yesterday | Daily Political

    Delcath Systems Inc. dropped 5.4% during trading on Wednesday . The stock traded as low as $2.80 and last traded at $2.96, with a volume of 107,490 shares changing hands.

    Comment?

  5. Delcath Systems Inc. (DCTH) Hits New 1-Year Low at $3.32Read the original story w/Photo

    Tuesday Jul 26 | Daily Political

    Shares of Delcath Systems Inc. reached a new 52-week low on Tuesday . The company traded as low as $3.32 and last traded at $3.34, with a volume of 21,159 shares.

    Comment?

  6. Delcath Systems Inc. (DCTH) Hits New 12-Month High at $3.79Read the original story w/Photo

    Saturday Jul 23 | Daily Political

    Delcath Systems Inc. reached a new 52-week high during trading on Thursday . The company traded as high as $3.79 and last traded at $3.47, with a volume of 50,945 shares trading hands.

    Comment?

  7. Delcath Systems Inc. (DCTH) Sets New 1-Year High at $3.79Read the original story w/Photo

    Thursday Jul 21 | Daily Political

    Delcath Systems Inc. shares reached a new 52-week high during mid-day trading on Thursday . The stock traded as high as $3.79 and last traded at $3.47, with a volume of 50,945 shares trading hands.

    Comment?

  8. Delcath Announces Acceptance Of Abstracts For Poster Presentation At CIRSE 2016Read the original story

    Monday Jul 18 | Freshnews

    NEW YORK, July 18, 2016 /PRNewswire/ - Delcath Systems, Inc. , a specialty pharmaceutical and medical device company focused on oncology with an emphasis on the treatment of primary and metastatic liver cancers, announces that abstracts from two studies conducted in Germany of use of the Delcath Hepatic CHEMOSAT Delivery System to treat patients with liver metastases, have been accepted for presentation as posters at the Cardiovascular and Interventional Radiology Society of Europe annual meeting. The abstracts are: Percutaneous Isolated Hepatic Perfusion In Patients With Primary Or Secondary Liver Tumours: Experience In 20 Patients , by S. Marquardt, et al, of Hanover Medical School in Hanover, Germany.

    Comment?

  9. Outcomes Study On Delcath Systems's Melphalan/HDS In The Treatment Of ...Read the original story

    Wednesday Jul 6 | BioSpace

    Outcomes Study On Delcath Systems 's Melphalan/HDS In The Treatment Of Hepatic Metastases To Be Published In Cancer Control /PRNewswire/ -- Delcath Systems, Inc. , a specialty pharmaceutical and medical device company focused on the treatment of primary and metastatic liver cancers, announces that a review of clinical research treatment outcomes using Melphalan Hydrochloride for Injection with the Delcath Hepatic Delivery System in patients with hepatic metastases has been accepted for publication in the prestigious journal, Cancer Control .

    Comment?

  10. European Data Supporting Survival Benefit With Delcatha s CHEMOSAT System Presented At 6th European...Read the original story

    Wednesday Jul 6 | Freshnews

    Delcath Systems, Inc. , a specialty pharmaceutical and medical device company focused on treatment of primary and metastatic liver cancers, announces that data from a large single hospital experience conducted at Southampton University Hospital in the United Kingdom were presented in an oral presentation at the 6 European Post-Chicago Melanoma/Skin Cancer Meeting held in Munich, Germany from June 30 - July 1, 2016. The abstract, Chemosaturation Via Percutaneous Hepatic Perfusion - An Update On A Single Centre Experience Of Treating Metastatic Uveal Melanoma, Southampton University was presented by lead author, Ioannis Karydis, M.D, of Southampton University Hospital.

    Comment?

  11. European Data Supporting Survival Benefit With Delcath Systems's CHEMOSAT System Presented AtRead the original story

    Tuesday Jul 5 | BioSpace

    European Data Supporting Survival Benefit With Delcath Systems 's CHEMOSAT System Presented At 6th European Post-Chicago Melanoma/Skin Cancer Meeting /PRNewswire/ -- Delcath Systems, Inc. , a specialty pharmaceutical and medical device company focused on treatment of primary and metastatic liver cancers, announces that data from a large single hospital experience conducted at Southampton University Hospital in the , M.D, of Southampton University Hospital. Researchers conducted a retrospective evaluation of 27 metastatic uveal melanoma patients treated with CHEMOSAT over four years, analyzing survival, tumor response, time to progression and treatment related adverse events.

    Comment?

  12. Delcath Systems Inc. (DCTH) Shares Bought by Renaissance Technologies LLCRead the original story w/Photo

    Tuesday Jul 5 | Daily Political

    Renaissance Technologies LLC raised its position in Delcath Systems Inc. by 5.3% during the first quarter, Holdings Channel reports. The fund owned 682,498 shares of the medical device company's stock after buying an additional 34,500 shares during the period.

    Comment?

  13. Byte Ltd Sparkle Buys 3,753,855 Shares of CASI Pharmaceuticals Inc (CASI) StockRead the original story w/Photo

    Friday Jul 1 | Daily Political

    CASI Pharmaceuticals Inc major shareholder Byte Ltd Sparkle bought 3,753,855 shares of the business's stock in a transaction on Friday, June 24th. The stock was acquired at an average cost of $1.19 per share, for a total transaction of $4,467,087.45.

    Comment?

  14. CASI Pharmaceuticals Inc (CASI) Major Shareholder Buys $4,467,087.45 in StockRead the original story w/Photo

    Wednesday Jun 29 | AmericanBankingNews.com

    CASI Pharmaceuticals Inc major shareholder Byte Ltd Sparkle acquired 3,753,855 shares of CASI Pharmaceuticals stock in a transaction on Friday, June 24th. The shares were purchased at an average cost of $1.19 per share, with a total value of $4,467,087.45.

    Comment?

  15. Delcath Systems, Inc. (DCTH) Short Interest UpdateRead the original story w/Photo

    Jun 26, 2016 | Daily Political

    Delcath Systems, Inc. was the recipient of a significant increase in short interest in the month of June. As of June 15th, there was short interest totalling 2,728,779 shares, an increase of 104.9% from the May 31st total of 1,332,016 shares.

    Comment?

  16. Delcath Systems European Patient Education Website Receives Prestigious Digital Health AwardRead the original story

    Jun 22, 2016 | BioSpace

    The website was developed as an education and support resource for European patients and their families who are coping with the devastating diagnosis of cancer in the liver. The site provides patient-friendly content and videos that clearly explain the different types of liver cancers as well as the tests and screening tools used in the diagnosis process.

    Comment?

  17. Delcath Systems Announces Acceptance Of Abstract For Presentation At...Read the original story

    Jun 15, 2016 | BioSpace

    Additional information about the Post- scientific program can be found here and the complete abstract will be available for download approximately 10 days prior to the congress. Delcath Systems, Inc. is a specialty pharmaceutical and medical device company focused on oncology with a principal focus on the treatment of primary and metastatic liver cancers.

    Comment?

  18. City of Hope Release: Autologous Stem Cell Transplantation Offers...Read the original story

    Jun 13, 2016 | BioSpace

    Multicenter, phase II trial suggests autologous transplant should be standard of care for HIV patients with relapsed/treatment-resistant lymphoma "This is an important study because we need to better understand the long-term effects of HIV infection to ensure that patients are equitably treated in a way that respects their medical regimens and the biology of their HIV infection" According to researchers, people with HIV-associated lymphoma who receive autologous stem cell transplant have similar survival rates and are no more at risk of serious complications compared to those without HIV receiving this therapy.

    Comment?

  19. Autologous Stem Cell Transplantation Offers Safe and Effectiveand...Read the original story

    Jun 13, 2016 | PressReleasePoint

    New research published online today in Blood , the Journal of the American Society of Hematology , challenges the generally held belief that individuals with HIV and aggressive lymphoma are not candidates for standard treatment. According to researchers, people with HIV-associated lymphoma who receive autologous stem cell transplant have similar survival rates and are no more at risk of serious complications compared to those without HIV receiving this therapy.

    Comment?

  20. Autologous stem cell transplant should be standard care for HIV-associated lymphomaRead the original story w/Photo

    Jun 13, 2016 | PhysOrg Weblog

    New research published online today in Blood Journal of the American Society of Hematology , challenges the generally held belief that individuals with HIV and aggressive lymphoma are not candidates for standard treatment. According to researchers, people with HIV-associated lymphoma who receive autologous stem cell transplant have similar survival rates and are no more at risk of serious complications compared to those without HIV receiving this therapy.

    Comment?